Market Access/ News/ News AZ considers options as US gout drug deal backfires Richard Staines AstraZeneca, gout, Grunenthal, Ironwood, market access 0 Comment Ironwood tears up licensing agreement after sales disappoint Share X AZ considers options as US gout drug deal backfires https://pharmaphorum.com/news/az-considers-options-drug-deal-backfires/
News/ US FDA approves Ironwood’s gout combination drug Richard Staines arthritis, AstraZeneca, FDA approvals 2017, gout, Ironwood Pharmaceuticals 0 Comment Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning. Share X FDA approves Ironwood’s gout combination drug https://pharmaphorum.com/news/fda-approves-ironwoods-gout-combination-drug/
News AZ sells US, EU and Latin America rights to gout drug Richard Staines AstraZeneca, AZ, Financial, gout, Grunenthal, Zurampic 0 Comment AZ focused on sales target set by CEO Pascal Soriot. Share X AZ sells US, EU and Latin America rights to gout drug https://pharmaphorum.com/news/az-sells-us-eu-and-latin-america-rights-to-gout-drug/